Drugs / CART-19 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02135406 | May 2014 → Sep 2015 | plasma cell myeloma | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-19 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02135406 ↗ |
| Known as | CTL019 | “A patient with refractory multiple myeloma received an infusion of CTL019 cells, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric...” PMID 26352815 ↗ Sep 2015 |
| Modality | Cell therapy | “a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric antigen receptor” PMID 26352815 ↗ Sep 2015 |
| Route | Intravenous | “administered by intravenous infusion” NCT02135406 ↗ |
| Target | CD19 | “autologous T cells transduced with an anti-CD19 chimeric antigen receptor” PMID 26352815 ↗ Sep 2015 |